Experimental combo therapy targets tough leukemia
NCT ID NCT05507827
First seen Sep 30, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This early-stage trial tests whether adding specially engineered donor immune cells (CAR T cells) to a stem cell transplant is safe for adults with a high-risk type of leukemia called B-cell ALL. About 22 participants will receive a strong chemotherapy conditioning, a special stem cell product (Orca-T), and then the donor CAR T cells. The goal is to see if this approach can help prevent the cancer from coming back without causing severe side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.